In brief: C3, SSH, Axon

By Ruth Beran
Wednesday, 30 November, 2005

Clinical Cell Culture's (ASX:CCE) co-founder Prof Fiona Wood will step down from the company's board on December 31. She will remain as a consultant, an R&D partner through her research vehicle the McComb Foundation, and a substantial shareholder.

Shareholders at SSH Medical's (ASX:SSH) AGM yesterday approved a resolution to change the company's name to BioLayer Corporation, the unlisted Brisbane-based materials sciences company it acquired earlier this month.

Axon Instruments founder and former CEO Dr Alan Finkel has been appointed to the ATSE Clunies Ross board of governors. Finkel is the first winner of an ATSE Clunies Ross award to join the board.

Related News

Noxopharm says paper reveals science behind its immune system platform

Clinical-stage Australian biotech company Noxopharm Limited says a Nature Immunology...

Neurosensing/neurostimulation implants session to be held on Monday

On Monday, a session at UNSW Sydney will include people who are benefiting from bioelectronics...

argenx and Monash University partner against autoimmune diseases

To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd